A recent report by Ribas and Puig-Saus et al., showed that TYRP1 targeting CAR T cell therapy demonstrated significant antitumor in tumor cells with high TYRP1 expression in murine and patient-derived cutaneous, acral, and uveal melanoma models. This evidence concerns the gene TYRP1 and neoplasm.